INTERCEPT™ Blood System: The New Standard in Pathogen Inactivation
The INTERCEPT™ Blood System offers advanced pathogen inactivation technology that ensures the highest level of safety in plasma and platelet transfusions. By effectively neutralizing a wide range of viruses, bacteria and parasites, the system minimizes the risk of transfusion-transmitted infections, while fully preserving the therapeutic efficacy of blood components.
Technological superiority and reliability
The compact and intuitive design of the INT200 illuminator optimizes laboratory workflows, providing speed and exceptional reliability in blood product processing. It is a clinically proven solution that puts patient safety as the top priority in situations where every transfusion is critical.
Proven efficacy and scientifically validated safety
The INTERCEPT™ System is built on a solid foundation of scientific research and large-scale practical applicability. The efficacy of the pathogen inactivation (PI) process is supported by comprehensive clinical evidence and rigorous validation protocols.
- Validated safety: Every technical claim regarding pathogen neutralization is supported by detailed studies confirming the reliability of the system through the annual processing of nearly 2.5 million units of platelet concentrate.
- Global verification: The technology is preferred by over 300 blood centers in more than 40 countries. It is subject to ongoing monitoring, providing a continuous stream of data on its safety and effectiveness in real-world settings.
- Evidence-based approach: The inactivation process is designed to provide maximum protection without compromising the functional integrity of the blood components – a fact documented in numerous independent scientific publications and clinical trials.
The INTERCEPT Blood System is the preferred choice in over 300 blood centers in more than 40 countries, processing nearly 2.5 million units of platelets each year.
